Long-term effects of high-efficiency on-line haemodiafiltration on uraemic toxicity. A multicentre prospective randomized study

Nephrology Dialysis Transplantation

Volumn 26, Issue 8, 2011, Pages 2617-2624

  Pedrini, Luciano A ^a   De Cristofaro, Vincenzo ^b   Comelli, Mario ^c   Casino, Francesco G ^d   Prencipe, Mario ^e   Baroni, Adriana ^f   Campolo, Gesualdo ^f   Manzoni, Celestina ^f   Col, Luigi ^g   Ruggiero, Pio ^a   Acquistapace, Irene ^b   Auriemma, Laura ^a  

^a BOLOGNINI HOSPITAL   (Italy)

^b Hospital of Sondrio   (Italy)

^c UNIVERSITY OF PAVIA   (Italy)

^d Ospedale Civile di Matera   (Italy)

^e Cernusco sul Naviglio   (Italy)

^f Policlinico SOrsola Malpighi ^*

^g UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

beta2 microglobulin; haemodiafiltration; high flux; homocysteine; parathyroid hormone

Indexed keywords

ALUMINUM HYDROXIDE; BETA 2 MICROGLOBULIN; C REACTIVE PROTEIN; CALCITRIOL; CALCIUM ACETATE; CALCIUM CARBONATE; ERYTHROPOIETIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; N(G),N(G) DIMETHYLARGININE; PARATHYROID HORMONE; PHOSPHATE; PHOSPHATE BINDING AGENT; SEVELAMER; TRIACYLGLYCEROL; UREA;

ADULT; AGED; AMINO ACID BLOOD LEVEL; ANEMIA; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CROSSOVER PROCEDURE; FEMALE; HEMODIAFILTRATION; HEMODIALYSIS; HUMAN; HYPERPHOSPHATEMIA; INTERMETHOD COMPARISON; ITALY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ONLINE SYSTEM; OPEN STUDY; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SECONDARY HYPERPARATHYROIDISM; THERAPY EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; UREMIA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CROSS-OVER STUDIES; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HEMODIAFILTRATION; HUMANS; INTERVENTION STUDIES; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; ONLINE SYSTEMS; PROSPECTIVE STUDIES; SURVIVAL RATE; TIME; TOXINS, BIOLOGICAL; TREATMENT OUTCOME; UREMIA; YOUNG ADULT;

EID: 79958116756     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfq761     Document Type: Article

References (45)

1. Cheung AK, Levin NW, Greene T et al. Effects of high-flux hemodialysis on clinical outcomes: results of the HEMO study. J Am Soc Nephrol 2003;14:3251-3263 (Pubitemid 37509301)
2. Locatelli F, Martin-Malo A, Hannedouche T et al. Effect of membrane permeability on survival of hemodialysis patients. J Am Soc Nephrol 2009;20:645-654
3. Canaud B, Bragg-Gresham JL, Marshall MR et al. Mortality risk for patients receiving hemodiafiltration versus hemodialysis: European results from the DOPPS. Kidney Int 2006;69:2087-2093 (Pubitemid 43924275)
4. Vilar E, Fry AC, Wellsted D et al. Long-term outcomes in online hemodiafiltration and high-flux hemodialysis: a comparative analysis. Clin J Am Soc Nephrol 2009;12:1944-1953
5. Lin CL, Huang CC, Yu CC et al. Reduction of advanced glycation end product levels by on-line hemodiafiltration in long-term hemodialysis patients. Am J Kidney Dis 2003;42:524-531
6. Meert N, Eloot S, Waterloos MA et al. Effective removal of proteinbound uraemic solutes by different convective strategies: a prospective trial. Nephrol Dial Transplant 2009;24:562-570
7. Vaslaki L, Major L, Berta K et al. On-line haemodiafiltration versus haemodialysis: stable haematocrit with less erythropoietin and improvement of other relevant blood parameters. Blood Purif 2006;24:163-173 (Pubitemid 43259169)
8. Ward RA, Schmidt B, Hullin J et al. A comparison of on-line hemodiafiltration and high-flux hemodialysis: a prospective clinical study. J Am Soc Nephrol 2000;11:2344-2350
9. Vanholder R, De Smet R, Glorieux G et al. Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int 2003;63:1934-1943 (Pubitemid 36513344)
10. The EBPG Expert Group on Haemodialysis. European best practice guidelines for haemodialysis. Part 1. Nephrol Dial Transplant 2002;17(Suppl 7):7-109
11. Pedrini LA, De Cristofaro V. On-line mixed hemodiafiltration with a feedback for ultrafiltration control: effect on middle-molecule removal. Kidney Int 2003;64:1505-1513 (Pubitemid 37153819)
12. Pedrini LA, Cozzi G, Faranna P et al. Transmembrane pressure modulation in high-volume mixed hemodiafiltration to optimize efficiency and minimize protein loss. Kidney Int 2006;69:573-579 (Pubitemid 43164452)
13. Daugirdas JT. Simplified equations for monitoring Kt/V, PCRn, eKt/V, and ePCRn. Adv Ren Replace Ther 1995;2:295-304
14. Marra M, Bonfigli AR, Testa R et al. High-performance liquid chromatographic assay of asymmetric dimethylarginine, symmetric dimethylarginine, and arginine in human plasma by derivatization with naphthalene-2, 3-dicarboxaldehyde. Anal Biochem 2003;318:13-17 (Pubitemid 36627477)
15. Fleiss JL. The Cross-Over Study. The Design and Analysis of Clinical Experiments. New York: John Wiley & sons, 1986;263-281
16. Bostom AG, Shemin D, Lapane KL et al. Hyperhomocysteinemia and traditional cardiovascular disease risk factors in end-stage renal disease patients on dialysis: a case-control study. Atherosclerosis 1995;114:93-103
17. Manns BJ, Burgess ED, Hyndman ME et al. Hyperhomocyst (e) inemia and the prevalence of atherosclerotic vascular disease in patients with end-stage renal disease. Am J Kidney Dis 1999;34:669-677 (Pubitemid 29473054)
18. Robinson K, Gupta A, Dennis V et al. Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations. Circulation 1996;11:2743-2748 (Pubitemid 26411737)
19. The R Development Core Team. R version 1.7.1. The R Foundation ed. Vienna, Austria, http://www. R-project.org (2009, date last accessed)
20. Pinheiro JC, Bates DM. Statistics and Computing. Mixed Effects Models in S and S-PLUS. New York: Springer, 2000
21. Heinz J, Kropf S, Luley C et al. Homocysteine as a risk factor for cardiovascular disease in patients treated by dialysis: a meta-analysis. Am J Kidney Dis 2009;54:478-489
22. Vanholder R, Baurmeister U, Brunet P et al. A bench to bedside view of uremic toxins. J Am Soc Nephrol 2008;19:863-870
23. Barreto FC, Barreto DV, Liabeuf S et al. Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients. Clin J Am Soc Nephrol 2009;4:1551-1558
24. Liabeuf S, Barreto DV, Barreto FC et al. Free p-cresylsulphate is a predictor of mortality in patients at different stages of chronic kidney disease. Nephrol Dial Transplant 2009;25:1183-1191
25. De Vriese AS, Langlois M, Bernard D et al. Effect of dialyser membrane pore size on plasma homocysteine levels in haemodialysis patients. Nephrol Dial Transplant 2003;18:2596-2600 (Pubitemid 37483794)
26. van Tellingen A, Grooteman MP, Bartels PC et al. Long-term reduction of plasma homocysteine levels by super-flux dialyzers in hemodialysis patients. Kidney Int 2001;59:342-347 (Pubitemid 32055243)
27. Canaud B, Morena M, Cristol JP et al. Beta2-microglobulin, a uremic toxin with a double meaning. Kidney Int 2006;69:1297-1299
28. Cheung AK, Rocco MV, Yan G et al. Serum beta-2 microglobulin levels predict mortality in dialysis patients: results of the HEMO study. J Am Soc Nephrol 2006;17:546-555
29. Beerenhout CH, Luik AJ, Jeuken-Mertens SG et al. Pre-dilution online haemofiltration vs low-flux haemodialysis: a randomized prospective study. Nephrol Dial Transplant 2005;20:1155-1163 (Pubitemid 40862105)
30. Block GA, Klassen PS, Lazarus JM et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004;15:2208-2218 (Pubitemid 39031360)
31. Covic A, Kothawala P, Bernal M et al. Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of all-cause mortality, cardiovascular mortality and cardiovascular events in chronic kidney disease. Nephrol Dial Transplant 2009;24:1506-1523
32. Meyer TW, Leeper EC, Bartlett DW et al. Increasing dialysate flow and dialyzer mass transfer area coefficient to increase the clearance of protein-bound solutes. J Am Soc Nephrol 2004;15:1927-1935 (Pubitemid 38822074)
33. Leypoldt JK, Cheung AK, Agodoa LY et al. Hemodialyzer mass transfer-area coefficients for urea increase at high dialysate flow rates. The Hemodialysis (HEMO) Study. Kidney Int 1997;51:2013-2017 (Pubitemid 27252776)
34. Bonomini M, Ballone E, Di Stante S et al. Removal of uraemic plasma factor (s) using different dialysis modalities reduces phosphatidylserine exposure in red blood cells. Nephrol Dial Transplant 2004;19:68-74 (Pubitemid 38072617)
35. Bradbury BD, Critchlow CW, Weir MR et al. Impact of elevated C-reactive protein levels on erythropoiesis-stimulating agent (ESA) dose and responsiveness in hemodialysis patients. Nephrol Dial Transplant 2009;24:919-925
36. Carracedo J, Merino A, Nogueras S et al. On-line hemodiafiltration reduces the proinflammatory CD14+CD16+ monocyte-derived dendritic cells: a prospective, crossover study. J Am Soc Nephrol 2006;17:2315-2321 (Pubitemid 44141923)
37. Kuo HL, Chou CY, Liu YL et al. Reduction of pro-inflammatory cytokines through hemodiafiltration. Ren Fail 2008;30:796-800
38. Olsson J, Paulsson J, Dadfar E et al. Monocyte and neutrophil chemotactic activity at the site of interstitial inflammation in patients on high-flux hemodialysis or hemodiafiltration. Blood Purif 2009;28:47-52
39. Zoccali C, Bode-Boger S, Mallamaci F et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001;358:2113-2117 (Pubitemid 34094901)
40. Engelberger RP, Teta D, Henry H et al. Haemodialysis acutely reduces the plasma levels of ADMA without reversing impaired NO-dependent vasodilation. Clin Sci (Lond) 2009;117:293-303
41. Blankestijn PJ, Vos PF, Rabelink TJ et al. High-flux dialysis membranes improve lipid profile in chronic hemodialysis patients. J Am Soc Nephrol 1995;5:1703-1708
42. Goldberg IJ, Kaufman AM, Lavarias VA et al. High flux dialysis membranes improve plasma lipoprotein profiles in patients with end-stage renal disease. Nephrol Dial Transplant 1996;11(Suppl 2):104-107 (Pubitemid 26182552)
43. Wanner C, Bahner U, Mattern R et al. Effect of dialysis flux and membrane material on dyslipidaemia and inflammation in haemodialysis patients. Nephrol Dial Transplant 2004;19:2570-2575 (Pubitemid 39360106)
44. Seres DS, Strain GW, Hashim SA et al. Improvement of plasma lipoprotein profiles during high-flux dialysis. J Am Soc Nephrol 1993;3:1409-1415
45. Donauer J, Schweiger C, Rumberger B et al. Reduction of hypotensive side effects during online-haemodiafiltration and low temperature haemodialysis. Nephrol Dial Transplant 2003;18:1616-1622 (Pubitemid 36939637)